Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hematologic Neoplasms 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Obesity 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Motor Activity 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Colorectal Neoplasms 1Cardiotoxicity 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × Exercise Test × Clear all
NCT06008977 2026-03-25

EX-BOOST

AdventHealth Translational Research Institute

Phase NA Active not recruiting
12 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡